Excerpt from:
Societal CDMO Reports Inducement Grants for New Staff
Mendus redeems the outstanding convertible bonds from Negma Group
U.S. FDA approves Foundation Medicine’s FoundationOne®CDx as a companion diagnostic for Roche’s Rozlytrek® (entrectinib)
Tempest Reports Year End 2022 Financial Results and Provides Business Update
See the original post here:
Tempest Reports Year End 2022 Financial Results and Provides Business Update
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Rentschler implements innovative learning program in collaboration with MassBioEd and WPI
Valneva Completes BLA Submission to U.S. FDA for its Single-Shot Chikungunya Vaccine Candidate
Longeveron Inc. Provides Corporate Update and Reports Second Quarter 2022 Financial Results
CytomX Therapeutics to Present Phase 2 Data for Praluzatamab Ravtansine (CX-2009) in Patients with Advanced Breast Cancer at the San Antonio Breast…
Biofrontera Inc. Reports Second Quarter 2022 Financial Results and Provides a Business Update
VYNE Therapeutics Reports Second Quarter 2022 Financial Results
Crinetics Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
CENTOGENE Announces Shareholder Approval of All Resolutions at 2022 Annual General Meeting
Read the original here:
CENTOGENE Announces Shareholder Approval of All Resolutions at 2022 Annual General Meeting
Artelo Biosciences Presents Positive Pre-Clinical Results of ART26.12, a Novel FABP5 Inhibitor, in Alleviating Chemotherapy-Induced Pain
Capricor Therapeutics to Present One-Year Efficacy Results from its Ongoing HOPE-2 Open Label Extension Study at 2022 Parent Project Muscular…
Press Release: Nexviadyme® (avalglucosidase alfa) approved by European Commission as a potential new standard of care for the treatment of Pompe…
ImmixBio IMX-110 Demonstrated Improved Survival Over U.S. Food and Drug Administration Approved Drug Trabectedin (sold as YONDELIS ® by Janssen, a…
Santhera and ReveraGen to Present New Data with Vamorolone at 2022 Parent Project Muscular Dystrophy Conference
Nuvectis Pharma to Present in the H.C. Wainwright Global Investment Conference
View original post here:
Nuvectis Pharma to Present in the H.C. Wainwright Global Investment Conference